checkAd

     917  0 Kommentare Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study - Seite 3

    Contacts:
    Cleveland BioLabs, Inc.
    C. Neil Lyons
    Chief Financial Officer
    T: 301-675-4570
    E: nlyons@cbiolabs.com

    Lesen Sie auch


    Seite 3 von 3
    Verfasst von Marketwired
    Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study - Seite 3 BUFFALO, NY--(Marketwired - Apr 17, 2017) -  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of a side-by-side analytical comparison of two formulations of entolimod. …